SUMMARY While the antiarrhythmic effects of amiodarone are well-documented, its hemodynamic effects are not. We injected 5 mg/kg amiodarone i.v. in 16 patients undergoing coronary arteriography. Heart rate did not change. Aortic (systolic, diastolic and mean) and left ventricular (systolic and end-diastolic) pressures decreased significantly (p < 0.01) at 5 and 15 minutes; systemic vascular resistance also fell significantly (p < 0.05), while cardiac index increased slightly but significantly (p < 0.05). Coronary vascular resistance decreased significantly (p < 0.01) and coronary sinus blood flow rose in most patients, from a mean of 138 ml/min to 153 ml/min at 5 minutes (p < 0.02); it then returned toward the control value at 15 minutes (mean 145 ml/min). circulation. These studies indicate that amiodarone injected in a dosage known to produce therapeutic antiarrhythmic effects decreases myocardial 02 requirements without a decrease in myocardial blood flow. This decrease in myocardial 02 demand is the result of reduced heart rate, contractility, and afterload from systemic vasodilatation.
AMIODARONE (L3428*, 2 butyl-3-(3,5-diido-4f-diethylaminethoxybenzoyl)-benzofuran) was To our knowledge, only two reports in the literature have discussed the hemodynamic effects of amiodarone after intravenous administration in man;10' 11 only one of them dealt with its effects on the coronary *Amiodarone (Cordarone), manufactured by Labaz, Brussels, Belgium. Its structural formula is shown in figure 1. circulation. These studies indicate that amiodarone injected in a dosage known to produce therapeutic antiarrhythmic effects decreases myocardial 02 requirements without a decrease in myocardial blood flow. This decrease in myocardial 02 demand is the result of reduced heart rate, contractility, and afterload from systemic vasodilatation.
Material and Methods

Subjects
Sixteen subjects premedicated with a Nembutal suppository (200 mg) who were undergoing coronary angiography for chest pain were studied after an overnight fast. Exclusion criteria were as follows: presence of valvular heart disease, unstable angina, heart failure, recent myocardial infarction, uncontrolled diabetes and significant systemic hypertension. Table  1 details the clinical and angiographic characteristics of the patients. Two patients had normal coronary arteries with anginal pain and are included because of a response similar to that of patients with coronary heart disease.
Techniques
With the patient under local anesthesia, we inserted a #8 French Sones catheter into the right or left brachial artery to measure left ventricular and aortic pressures. We inserted a #8 French Ganz thermodilution catheter* from a right or left basilic vein into the coronary sinus to determine coronary sinus blood flow (CSBF), to take blood samples and to inject dye for measurement of cardiac output (CO).
Catheters were connected to Statham P23Db transducers, which were adjusted so that the zero pressure was at the mid-chest position. Pressures were Philips photographic recorder. At prescribed intervals, we took aortic and coronary sinus blood specimens simultaneously to determine hemoglobin, hematocrit, pH and blood gases, sodium and potassium, SMA 12/60,* lactate and the following enzymes: creatine phosphokinase (CPK), oxaloacetic transaminase (GOT), and total lactic dehydrogenase (LDH) and its five isoenzymes. CSBF was measured by thermodilution." Location of the coronary sinus ostium was confirmed by a small hand injection of contrast material and the external thermistor or distal pacing electrode of the Ganz catheter was positioned just inside the coronary sinus ostium and maintained in that position throughout the study. A physiologic saline solution at 22-25°C was injected into the coronary sinus, using a calibrated Harvard pump and twin syringes of 20 ml, at a constant rate of about 35-40 ml/min for 20-30 seconds. This relatively high injection rate allows adequate mixing of the injectate with blood. CSBF was obtained twice at rest in most patients, and did not vary more than 5%. CSBF in ml/min was obtained using the formula:
where Fi represents the volume of injectate (ml/min), Tb, Ti and Tm are temperatures of blood, injectate and mixture of blood and injectate (°C); 1.08 is a constant derived from the density and specific heat of the saline solution and blood.
CO was measured after rapid injection in the coronary sinus of 5 mg of indocyanine green, followed immediately by a saline flush. Central aortic blood was withdrawn by a Harvard infusion pump at a rate of 20 ml/min through a cuvette dye densitometer.
Computation of CO was performed with the use of the Williams formula. '4 Treatments The study was undertaken after left-heart and coronary sinus catheterization, and before left ventriculography and coronary arteriography. The control measurements described below were not carried *Technicon Corporation, Ardsley, New York (calcium, inorganic phosphate, glucose, urea nitrogen, uric acid, cholesterol, proteins, albumin, total bilirubin, alkaline phosphatase, total lactic dehydrogenase and creatinine). out until at least 10 minutes after catheter manipulations to achieve a stable basal state. The following procedures were accomplished in close temporal sequence: pressure recordings, blood sampling and determination of CSBF and CO.
After completing basal measurements, we injected an amiodarone dosage of 5 mg/kg of body weight into the coronary sinus over a 1-minute period. The patient was unaware that a drug was being administered. Measurements were repeated at 5-10 minutes and 15-20 minutes, and the drug study was completed within 30 minutes. In addition, heart rate (HR), left ventricular systolic pressure (LVSP) and left ventricular end-diastolic pressure (LVEDP) were continuously monitored during the first 5 minutes of amiodarone administration. Left ventriculography and selective coronary arteriography were then carried out. fig. 3 ).
Metabolic Data
Oxygen, Substrates and Enzymes. There was no change in the arterial and coronary sinus 02 concentrations after amiodarone, so myocardial 02 extraction was unchanged. The increase in myocardial 02 consumption from 13.8 ml/min at rest to 16.8 ml/min at 5 minutes (p < 0.05) was therefore secondary to the 1168 CI RCULATION EFFECTS OF AMIODARONE/Cot'e et al. concomitant simultaneous and equivalent increase in CSBF.
Mean myocardial extraction of lactate did not change significantly: 6.1 % in the control state, 9.3% at 5 minutes (NS) and 11.2% at 15 minutes (NS). However, five of the eight patients with lactate production at rest improved, shifting to extraction at 5 and 15 minutes of amiodarone, one patient had no change and lactate production further increased in two. Of the eight patients with lactate extraction, six were unchanged and in two patients, extraction shifted to production. Thus, in the 16 patients, lactate metabolism was unchanged in seven, improved in five and deteriorated in four, possibly indicating myocardial ischemia in the last four patients.
Arterial glucose concentration increased in 13 of the 14 patients in whom it was measured, from a mean of 108 mg/100 ml at rest to 120 mg/100 ml at 5 minutes (p < 0.01) and to 118 mg/100 ml at 15 minutes (p < 0.001). Since coronary sinus glucose concentration increased proportionally less than arterial glucose concentration, arterial-coronary sinus glucose difference rose significantly from a mean of 3.1 mg/ 100 ml at rest to 12.7 mg/100 ml at 5 minutes (p < 0.05) and 8.1 mg/100 ml at 15 minutes (NS), as well as the percentage of myocardial glucose extraction from 3.8% at rest to 9.3% at 5 minutes (p < 0.05) and to 7.8% at 15 minutes (NS).
One of the cardiac LDH isoenzymes, fraction 1, was significantly decreased in the coronary sinus 15 minutes after amiodarone, from 27% of total LDH to 22% (p < 0.05), while arterial concentration was unchanged at 26%; therefore, myocardial production of LDH1 at rest, mean of -2.5%, reversed to extraction at 15 min, + 3.8%; this change is slight and not significant. Arterial and coronary sinus concentrations of LDH, significantly increased at 5 and 15 minutes after the drug (p < 0.05); both changes were of the same magnitude, so no change in myocardial extraction or production occurred. The drug had no effect on other isoenzymes of LDH and on enzymes GOT and total CPK.
Other Substances. Amiodarone had no effect on the myocardial metabolism of Hb, Ht, Pco2, Po2, Na-K, calcium, inorganic phosphate, urea nitrogen, uric acid, cholesterol, proteins, albumin, total bilirubin, alkaline phosphatase and creatinine.
Clinical Effects
No complication occurred during the drug study and the angiographic procedures. Electrophysiologic effects were recently summarized by Rosenbaum et al. 7 The drug increases the refractory period of atrial and ventricular muscle and is therefore useful in the treatment of atrial and ventricular premature depolarizations; it also increases refractoriness of the atrioventricular node and HisPurkinje system, as well as in the anomalous pathways of patients with the Wolff-Parkinson-White syndrome, 6 16, 17 creating the most favorable conditions for prevention and interruption of any reentry mechanism in this and other types of tachycardia.
Experimental Hemodynamic Studies
Initial and more recent hemodynamic observations in laboratory animals reveal that amiodarone has intrinsic and extrinsic (anti-adrenergic) pharmacologic properties.3' 18 Direct effects of amiodarone are a slowing in heart rate, a decrease in pressure work of the heart without a decrease in flow, a fall in peripheral resistance, a modest decrease in contractility and an increase in coronary blood flow. These effects on systemic and coronary hemodynamics permit a favorable influence on the balance of oxygen supply and demand in myocardial ischemia.'8 Indirect effects of amiodarone have also been documented in experimental studies. This agent shows marked but partial antagonistic effects on various a-and ,B-adrenergic cardiovascular phenomena, such as hypertension and tachycardia induced by noradrenaline and adrenaline. However, amiodarone is not an a-or f-blocking agent.
Human Hemodynamic Studies
Few hemodynamic studies of amiodarone are available. Ourbak" injected intravenously 5 mg/kg of amiodarone in six patients with coronary artery disease and noted a decrease in HR of only 2-5 beats/min. This is similar to the results of the present study. Sicart'0 injected the drug, using the same dosage, in six patients catheterized because of heart murmur, but without significant hemodynamic lesion. He also observed no change in HR after 5-30 minutes, but then noted an acceleration at the end of the injection from 78 to 97 beats/min (69 to 79 beats/min in the present study). This reflexly mediated acceleration in HR is transient and probably related to the drop in blood pressure.
The predominant effect of amiodarone is a marked systemic vasodilatation and a hot feeling like that frequently experienced with the injection of contrast material during angiographic procedures. This dilatation is maximal at 2-3 minutes of the injection and, at that time, all arterial pressures are decreased. Left ventricular systolic and end-diastolic pressures decrease at 3 and 5 minutes and remain lower than resting values at 15 minutes. These effects on arterial pressure do not represent a negative effect of the drug, since should this have occurred, LVEDP would have increased and CI would have diminished.
In Sicart's study,10 LVSP decreased from 132 to 106 mm Hg at 5 minutes (132 mm Hg to 109 mm Hg in our study) and SVR decreased from 16 to 11 units (20 mm Hg to 16 mm Hg in our study). In the same study, LVEDP was also decreased at 5 minutes of 5 mg/kg of amiodarone. This fall in LVEDP at 5 minutes was more obvious when basal LVEDP was high. A decrease in venous return through venodilatation might explain this reduction of LVEDP. Unloading of the left ventricle through a decrease in afterload is probably responsible for this decrease in LVEDP as well as for the increase in CI. These effects of the drug on LVEDP, CI and stroke volume could also be related to both direct and indirect (increase in myocardial blood flow) increases in contractility. Contractility was not evaluated in this study.
CSBF increased in the patients with coronary artery disease, although perfusion pressure fell. Coronary vasodilatation occurred and explains the fall in CVR and the increase in CSBF. This mild increase in CSBF could also be due to coronary sinus blood reflux from the right atrium.'9 Right 'atrial pressure was not routinely measured in this study, but we would suspect a fall instead of a rise after amiodarone since this drug caused a decrease in SVR. In the only available study of the effects of this drug on myocardial flow,11' 19 CSBF was 138 ml/min at rest in six patients with coronary artery disease and was unchanged at 5, 15 and 30 minutes of the administration of 5 mg/kg of amiodarone.
This drug might also have effects on cardiac metabolism. Myocardial 02 extraction was unchanged; however, myocardial 02 consumption slightly increased, and this could be due to a solq increase in CSBF, since arterial-coronary sinus 02 difference was unchanged. This rise in myocardial 02 consumption and secondarily of CSBF could be due to enhancement of contractility.
Half of the patients we studied were ischemic at rest in terms of lactate metabolism, and many of them improved after amiodarone. Myocardial ischemia may have occurred in four patients with lactate production; when analyzing their clinical and hemodynamic data, we found the following explanations in one or more patients: absence of coronary and systemic vasodilatation, increase in TTI, or tachycardia. Arterial glucose concentration rose in these patients; since CSBF also increased, more glucose was available as a sourc¢ of energy to the heart. This effect of the drug on the myocardial metabolism of glucose might be beneficial in ischemia during myocardial infarction or coronary artery bypass surgery. This remains controversial, although there is a recent interest in the administration of this substrate with K and insulin.
Isoenzyme 1 of LDH favors conversion of lactate to pyruvate, which is converted to acetyl-CoA to enter the citric acid cycle, the most important source of energy production. This enzyme was not increased in the coronary sinus. Since its arterial concentration was unchanged, there was some extraction by the myocardium. One may speculate that this increase in LDH extraction by the heart after amiodarone parallels the improvement in lactate metabolism.
This study demonstrates that amiodarone used in parenteral form is a powerful direct vasodilator of the systemic and coronary vessels, and therefore these beneficial effects of amiodarone should be further evaluated in patients with coronary artery disease. The drug probably should not be used orally for an extended time because of its side effects. Thus, it may have a limited application in chronic angina pectoris and could be useful orally to control refractory arrhythmias over relatively short periods.
Its main benefit may be when used acutely to control arrhythmias or, as suggested in this study, as an afterload-reducing agent.
